MiNK Therapeutics, Inc. (NASDAQ:INKT) Sees Significant Increase in Short Interest

MiNK Therapeutics, Inc. (NASDAQ:INKT) saw a large increase in short interest in January. As of January 15th, there was short interest totalling 123,000 shares, an increase of 160.6% from the December 31st total of 47,200 shares. Approximately 1.2% of the shares of the company are short sold. Based on an average trading volume of 96,700 shares, the days-to-cover ratio is currently 1.3 days.

Analyst Ratings Changes

INKT has been the topic of several research analyst reports. HC Wainwright restated a “buy” rating and set a $90.00 price objective on shares of MiNK Therapeutics in a research note on Friday, November 15th. Robert W. Baird decreased their price target on shares of MiNK Therapeutics from $80.00 to $40.00 and set an “outperform” rating for the company in a report on Friday, November 15th.

Hedge Funds Weigh In On MiNK Therapeutics

A hedge fund recently raised its stake in MiNK Therapeutics stock. Renaissance Technologies LLC increased its holdings in MiNK Therapeutics, Inc. (NASDAQ:INKT) by 21.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 127,841 shares of the company’s stock after purchasing an additional 22,613 shares during the quarter. Renaissance Technologies LLC owned 0.37% of MiNK Therapeutics worth $121,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 2.87% of the company’s stock.

MiNK Therapeutics Stock Up 3.2 %

NASDAQ INKT traded up $0.22 during trading hours on Friday, hitting $7.11. The company had a trading volume of 5,122 shares, compared to its average volume of 47,024. The firm has a market cap of $28.16 million, a P/E ratio of -1.82 and a beta of 0.10. MiNK Therapeutics has a fifty-two week low of $4.56 and a fifty-two week high of $19.00. The business has a fifty day simple moving average of $7.21 and a 200-day simple moving average of $7.65.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.